03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
20:11 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular atrophy Patient sample and mouse studies suggest APLN could help treat age-related sarcopenia. In patients, plasma APLN levels were lower than in elderly volunteers without sarcopenia. In a mouse model of age-related sarcopenia, the...
21:41 , Jul 30, 2018 |  BC Extra  |  Preclinical News

Apelin is a potential sarcopenia therapeutic

A paper in Nature Medicine suggests that apelin (APLN) could help treat sarcopenia as well as serve as a biomarker of the age-related disease characterized by skeletal muscle loss. Researchers from University of Toulouse and colleagues...
15:00 , Aug 7, 2017 |  BC Extra  |  Preclinical News

NIH researchers identify genes essential for immunotherapy

In a paper published in Nature, researchers at NIH's NCI and colleagues identified about 100 genes that may be tied to immunotherapy resistance in cancer cells. The researchers used a CRISPR-Cas9 (CRISPR-associated protein 9) loss-of-function screen...
00:34 , Jun 30, 2017 |  BC Extra  |  Preclinical News

Hormone tied to treating preeclampsia

In a paper published in Science, researchers at Singapore's Agency for Science Technology and Research (A*STAR) show lack of a hormone normally secreted by the placenta in pregnant mice led to preeclampsia symptoms, and treatment...
20:32 , Feb 3, 2017 |  BC Week In Review  |  Company News

Sosei, University of Cambridge deal

Sosei’s Heptares Therapeutics subsidiary and the university partnered for three years to discover molecules that target and modulate apelin receptor (APLNR; APJ), a GPCR, to treat cardiovascular disease. Heptares will have rights to IP generated...
08:00 , Jan 24, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Apelin (APLN); microRNA-424 (miR-424); miR-503 In vitro and rodent...
07:00 , Aug 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Heart failure Apelin receptor (APLNR; APJ); apelin (APLN) In vitro and mouse studies suggest selectively targeting...
07:00 , Oct 13, 2011 |  BC Innovations  |  Strategy

Lilly's opening moves

When Eli Lilly and Co. launched its Phenotypic Drug Discovery Initiative in 2009, its goal was to apply a crowdsourcing approach to finding new small molecules from external investigators that fit the company's core disease...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Hypertension Apelin (APLN) Studies in patient samples and in mice suggest...